Acumen Pharmaceuticals Inc ABOS

$2.04 -0.03 (-1.45%)

Valuation

Market cap
149,696,000
Revenue TTM
$0
Net income TTM
$-121,340,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.55

Trading

Volume
580,500
Avg volume
436,968
Day's range
$2.02 – $2.10
Shares out
72,317,000
Stochastic %K
4%
Beta
0.33
Analysts
Strong Sell
Price target
$7.75

Price

Company profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc....

Show more

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 344 4190
Website
https://acumenpharm.com
Address
1210-1220 Washington St., Suite 210, Newton, United States

Latest news

Stocktwits

Biotech_Pharma_Investor Oct 1, 4:32 PM
We know anti-amyloid drugs work (with AEs). $ABOS has an oligomer-targeted antibody with randomized data expected later this year (dont see why it wont be positive given prior AD trials with anti-amyloid drugs). A positive readout from $ABOS would be great news for $PMN as they have the safest oligomer-targeted drug.
0 replies
Biotech_Pharma_Investor Oct 1, 3:32 PM
$PMN Getting cheaper and cheaper. Shouldnt it run towards $ABOS data later this year?
0 replies
RandomInvestor777 Sep 25, 7:51 PM
$ABOS What's everyone prediction if this hits? I think 10-12
2 replies
RandomInvestor777 Sep 18, 1:27 PM
$ABOS if LPLV end of sept, data readout late dec?
0 replies
st165576 Sep 17, 2:50 PM
$ABOS healthy volume and reversal underway
0 replies
st165576 Sep 16, 11:10 PM
$ABOS they would be looking for partner for ph 3 on a successful ph 2. abos still remains under radar. there are positive signs. here is link to investor day presentation. https://edge.media-server.com/mmc/p/m5f2y8k8/
0 replies
AlluvialFan Sep 16, 8:28 PM
$ABOS anybody pick up anything meaningful new from today’s investor day conference call. Thanks
0 replies
anachartanalyst Sep 15, 5:02 PM
$ABOS https://anachart.com/wp-content/uploads/2026/09/1789491700_soc-img.jpg
0 replies